Overview

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation Administered in Healthy Subjects and Multiple Doses in Patients With COPD

Status:
RECRUITING

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalationadministered in a single dose in healthy individuals and multiple doses in patients with COPD

Phase:

PHASE1

Details

Lead Sponsor:

Guangdong Hengrui Pharmaceutical Co., Ltd

Treatments:

Inhalation
Moxifloxacin